Natarajan Sethuraman
Fortune : 2 M $ au 31/05/2026
Fortune : 2 M $ au 31/05/2026
Natarajan Sethuraman currently works at Entrada Therapeutics, Inc., as President-Research & Development from 2024.
Dr. Sethuraman also formerly worked at Merck & Co., Inc., as Executive Director & Head-GlycoFi Site from 2012 to 2016 and Medical Enzymes AG, as Senior Scientist.
Dr. Sethuraman received his graduate degree and doctorate degree from Indian Agricultural Research Institute and undergraduate degree from Tamilnadu Agricultural University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENTRADA THERAPEUTICS INC 0,56 % | 04/05/2026 | 216 317 ( 0,56 % ) | 2 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2017 |
| Sociétés | Poste | Fin |
|---|---|---|
| MERCK & CO., INC. | Directeur/Membre du Conseil | 01/07/2016 |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Indian Agricultural Research Institute
Indian Agricultural Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tamilnadu Agricultural University
Tamilnadu Agricultural University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national